Some shareholder rights procedures are in place: convocation notice 4 weeks prior, electronic voting, avoidance of concentrated meeting dates.
However, no dividends paid and no dividend policy or mid-to-long-term shareholder return policy established, reducing predictability.
CEO succession policy not formalized, board entirely male (no gender diversity), and no individual performance evaluation for outside directors.
Internal audit support organization lacks independence (e.g., no personnel authority); external auditor post-selection evaluation not conducted, and non-audit services contract without pre-approval.
As a newly formed entity, governance foundation is laid, but further improvements needed in shareholder-friendly policies and transparency.
[AI Summary]Samyang Biopharm has established a basic governance framework as a newly spun-off entity, but urgent improvements are needed in shareholder value enhancement, including no dividends, lack of shareholder return policy, and board diversity deficiency. Particularly, institutional supplementation in CEO succession and external auditor independence is required, making substantive operational improvements of the board and audit mechanisms a key variable for future stock price outlook.